ATE340165T1 - Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben - Google Patents

Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben

Info

Publication number
ATE340165T1
ATE340165T1 AT02703421T AT02703421T ATE340165T1 AT E340165 T1 ATE340165 T1 AT E340165T1 AT 02703421 T AT02703421 T AT 02703421T AT 02703421 T AT02703421 T AT 02703421T AT E340165 T1 ATE340165 T1 AT E340165T1
Authority
AT
Austria
Prior art keywords
molecules
relates
present
combi
signal transmission
Prior art date
Application number
AT02703421T
Other languages
English (en)
Inventor
Bertrand J Jean-Claude
Fabienne Dudouit
Stephanie Matheson
Original Assignee
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mcgill filed Critical Univ Mcgill
Application granted granted Critical
Publication of ATE340165T1 publication Critical patent/ATE340165T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
AT02703421T 2001-02-26 2002-02-26 Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben ATE340165T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27086801P 2001-02-26 2001-02-26

Publications (1)

Publication Number Publication Date
ATE340165T1 true ATE340165T1 (de) 2006-10-15

Family

ID=23033147

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02703421T ATE340165T1 (de) 2001-02-26 2002-02-26 Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben

Country Status (6)

Country Link
US (1) US7572798B2 (de)
EP (1) EP1366027B1 (de)
AT (1) ATE340165T1 (de)
CA (1) CA2439143A1 (de)
DE (1) DE60214828T2 (de)
WO (1) WO2002068396A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100735639B1 (ko) 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
AU2007296746B2 (en) 2006-09-11 2012-07-05 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
JP2010502741A (ja) 2006-09-11 2010-01-28 キュリス，インコーポレイテッド Ｐｔｋインヒビターとしての亜鉛結合部分を含む置換２−インドリノン
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
AU2007296743B2 (en) 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
WO2009035718A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety
TW200922564A (en) 2007-09-10 2009-06-01 Curis Inc CDK inhibitors containing a zinc binding moiety
CN101619043B (zh) * 2008-06-30 2013-06-05 和记黄埔医药（上海）有限公司 喹唑啉衍生物及其医药用途
US8426430B2 (en) * 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
CN102485735B (zh) * 2010-12-02 2014-09-24 东莞南方医大代谢医学研发有限公司 6-果糖氨-4-芳胺基喹唑啉衍生物及其用途
CN119019408B (zh) * 2024-08-15 2025-02-28 中山大学附属第三医院 Egfr-mek-tz三联合分子ln-1及其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives

Also Published As

Publication number Publication date
US20040086907A1 (en) 2004-05-06
EP1366027B1 (de) 2006-09-20
WO2002068396A1 (en) 2002-09-06
CA2439143A1 (en) 2002-09-06
DE60214828T2 (de) 2007-09-06
EP1366027A1 (de) 2003-12-03
US7572798B2 (en) 2009-08-11
DE60214828D1 (de) 2006-11-02

Similar Documents

Publication Publication Date Title
ATE532860T1 (de) B7-ähnliche moleküle und deren anwendungen
NL300933I2 (nl) Letermovir
ATE340165T1 (de) Kombi-moleküle, welche eine inhibierende wirkung auf die signalübertragung und dna-schädigende eigenschaften haben
DE60204722D1 (de) Quinazolinderivate für die behandlung durch t-zellen vermittelter krankheiten
DE69503129D1 (de) Pteridin-nukleotidderivate als fluoreszierende sonden
MXPA02012681A (es) Compuestos de sales de ditosilato de quinazolina.
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
ATE313532T1 (de) Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
ATE355278T1 (de) Isochinolinon derivate als parp inhibitoren
PL326925A1 (en) Substituted aryl or heteroaryl amides exhibiting retin-like biological activity
WO2003005999A3 (en) Methods of treating cytokine mediated diseases
ATE455092T1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
EP1350763A4 (de) Sapo-11 molekularsieb : sein syntheseverfahren und katalysator das molekularsieb enthaltend
ITBO20020620A1 (it) Condotto multi-canale bioriassorbibile di rigenerazione del nervo e processo per preparare il medesimo.
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
WO2003082268A3 (en) Hemiasterlin derivatives and uses thereof in the treatment of cancer
WO2001072685A3 (en) Polyamine analogues as cytotoxic agents
NO20055741D0 (no) Nye kjemiske forbindelser
WO2002081745A3 (en) Genes involved in osteogenesis, and methods of use
WO2005030794A3 (en) Hemiasterlin derivatives and uses thereof
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
TW200503672A (en) 2-aminobenzoyl derivatives
EP1573023A4 (de) Nukleinsäure und dieser entsprechendes, 162p1e6 genanntes, für die behandlung und den nachweis von krebs geeignetes protein
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties